Skip to content

Brief Interventions for Drop-out Re-engagement

Adaptive Brief Interventions for Drop-out Re-engagement

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00350571
Enrollment
299
Registered
2006-07-11
Start date
2004-11-30
Completion date
2009-11-30
Last updated
2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Abuse

Keywords

behavior therapy, counseling, drug abuse therapy, outpatient care, therapy compliance, clinical trial phase I, coping, outcomes research, satisfaction, social psychology, patient oriented research

Brief summary

We will evaluate a series of interventions intended to help individuals who drop out of substance abuse treatment re-engage in order to improve treatment outcome.

Detailed description

We propose a 5-year Stage I behavioral therapy development study to: 1) prospectively evaluate risk factors for premature drop-out from outpatient treatment; 2) develop and test a manual of single session phone-and office-based interventions to re-engage these individual in treatment.

Interventions

BEHAVIORALbrief (behavioral therapy)

up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.

BEHAVIORALDrop out re-engagement motivational intervention

Up to 3 phone or office based counseling sessions to promote reengagement in treatment

BEHAVIORALstandard care follow up

routine counselor phone calls and letters

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* admission to outpatient treatment

Exclusion criteria

* need for hospitalization

Design outcomes

Primary

MeasureTime frame
retention into outpatient treatment4, 8, 12, 24 weeks

Secondary

MeasureTime frame
substance abuse4, 8,12,and 24 weeks
psychiatric symptoms4, 8, 12, and 24 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026